EP0689603A1 - Defektiver mutanter nicht-retroviraler virus (2.b.hsv) zum impstoff - Google Patents
Defektiver mutanter nicht-retroviraler virus (2.b.hsv) zum impstoffInfo
- Publication number
- EP0689603A1 EP0689603A1 EP94909990A EP94909990A EP0689603A1 EP 0689603 A1 EP0689603 A1 EP 0689603A1 EP 94909990 A EP94909990 A EP 94909990A EP 94909990 A EP94909990 A EP 94909990A EP 0689603 A1 EP0689603 A1 EP 0689603A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hsv
- virus
- pharmaceutical
- disc
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 202
- 229960005486 vaccine Drugs 0.000 title claims abstract description 47
- 230000002950 deficient Effects 0.000 title claims abstract description 17
- 230000001177 retroviral effect Effects 0.000 title claims abstract description 16
- 208000015181 infectious disease Diseases 0.000 claims abstract description 65
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 241000700584 Simplexvirus Species 0.000 claims abstract description 36
- 101150055782 gH gene Proteins 0.000 claims abstract description 36
- 230000002458 infectious effect Effects 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 22
- 230000003612 virological effect Effects 0.000 claims abstract description 18
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 17
- 230000010076 replication Effects 0.000 claims abstract description 16
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 9
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 9
- 208000009889 Herpes Simplex Diseases 0.000 claims abstract description 8
- 230000007547 defect Effects 0.000 claims abstract description 7
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims abstract description 6
- 230000003902 lesion Effects 0.000 claims description 23
- 108020004414 DNA Proteins 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- 241001529453 unidentified herpesvirus Species 0.000 claims description 7
- 206010061978 Genital lesion Diseases 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 230000001815 facial effect Effects 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 118
- 238000002255 vaccination Methods 0.000 description 69
- 241001465754 Metazoa Species 0.000 description 61
- 201000010099 disease Diseases 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 24
- 239000012636 effector Substances 0.000 description 24
- 239000012634 fragment Substances 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 19
- 108091034117 Oligonucleotide Proteins 0.000 description 16
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 16
- 238000002649 immunization Methods 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 230000005951 type IV hypersensitivity Effects 0.000 description 16
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 241000700198 Cavia Species 0.000 description 15
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 15
- 230000000306 recurrent effect Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 206010015150 Erythema Diseases 0.000 description 13
- 231100000321 erythema Toxicity 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 10
- 230000006798 recombination Effects 0.000 description 10
- 238000005215 recombination Methods 0.000 description 10
- 210000003501 vero cell Anatomy 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 210000000624 ear auricle Anatomy 0.000 description 9
- 240000001307 Myosotis scorpioides Species 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002238 attenuated effect Effects 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 210000000609 ganglia Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229960000380 propiolactone Drugs 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000032420 Latent Infection Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000700589 Herpes simplex virus (type 1 / strain 17) Species 0.000 description 1
- 241000700328 Herpes simplex virus (type 1 / strain F) Species 0.000 description 1
- 241000700327 Herpes simplex virus (type 1 / strain MP) Species 0.000 description 1
- 241000700321 Herpes simplex virus (type 1 / strain SC16) Species 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000701069 Human herpesvirus 2 strain G Species 0.000 description 1
- 241000701072 Human herpesvirus 2 strain HG52 Species 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
- 101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 101150105144 UL21 gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 101150118163 h gene Proteins 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
Definitions
- Viral vaccines are traditionally of two sorts.
- the first sort are 'killed' vaccines, which are virus preparations which have been killed by treatment with a suitable chemical such as beta-propriolactone.
- the second type are live 'attenuated' vaccines, which are viruses which have been rendered less pathogenic to the host, either by specific genetic manipulation of the virus genome, or, more usually, by passage in some type of tissue culture system.
- kill vaccines do not replicate in the host, they are usually administered by injection, and hence may generate an inappropriate kind of immune response.
- the Salk vaccine a killed preparation of poliovirus, produces an imunoglobulin (Ig) G antibody response, but does not stimulate the production of IgA in the gut, the natural site of primary infection.
- Ig imunoglobulin
- this vaccine though it can protect the individual from the neurological complications of poliomyelitis, does not block primary infection, and so does not confer "herd immunity”.
- killed viruses do not enter and replicate inside host cells. Hence any beneficial immunological response to non-structural proteins produced during replication is not available. They also often fail to stimulate the production of cytotoxic T cells directed against virus antigens. "Dead" antigens can be picked up by antigen presenting cells and presented to T cells.
- the presentation occurs via MHC Class II molecules and leads to stimulation of T helper cells.
- the T helper cells help B cells to produce specific antibody against the antigen.
- virus antigens In order to stimulate the production of cytotoxic T cells, virus antigens must be processed through a particular pathway inside the infected cell, and presented as broken-up peptide fragments on MHC Class I molecules. This degradation pathway is thought to work most effectively for proteins that are synthesised inside the infected cell, and hence only virus that enters host cells and expresses immunogenic viral protein is capable of generating virus-specific cytotoxic T cells. Therefore, killed vaccines are poor inducers of cytotoxic T cells against virus infection. From this point of view, live attenuated vaccines are more satisfactory.
- live attenuated viruses have been made by deleting an inessential gene or partly damaging one or more essential genes (in which case, the damage is such that the genes are still functional, but do not operate so effectively).
- live attenuated viruses' often retain residual pathogenicity which can have a deleterious effect on the host.
- the attenuation is caused by a specific deletion, there remains the possibility of reversion to a more virulent form. Nevertheless, the fact that some viral protein production occurs in the host means that they are often more effective than killed vaccines which cannot produce such viral protein.
- Live attenuated viruses can also be used as 'vaccine vectors' for other genes, in other words carriers of genes from a second virus (or other pathogen) against which protection is required.
- members of the pox virus family eg. vaccinia virus, are used as vaccine vectors.
- vaccinia virus members of the pox virus family
- adenoviruses For adenoviruses, a human cell line was transformed with fragments of adenovirus type 5 DNA (Graham, Smiley, Russell & Nairn, J. Gen. Virol., 36, 59- 72, 1977). The cell line expressed certain viral genes, and it was found that it could support the growth of virus mutants which had those genes deleted or inactivated
- WO92/05263 published on 2 April 1992 provides a mutant non-retroviral virus whose genome is defective in respect of a gene essential for the production of infectious virus, such that the virus can infect normal cells and undergo replication and expression of viral antigen genes in those cells but cannot produce normal infectious virus.
- Mutant non-retroviral viruses in accordance with the teaching of WO92/05263 provide a unique way of combining the efficacy and safety of a killed vaccine with the extra immunological response induced by the in vivo production of viral protein by the attenuated vaccine.
- the invention of WO92/05263 comprises two features. Firstly, a selected gene is inactivated within the virus genome, usually by creating a specific deletion.
- This gene will be involved in the production of infectious virus, but preferably not preventing replication of the viral genome.
- the infected cell can produce more viral protein from the replicated genetic material, and in some cases new virus particles may be produced, but these would not be infectious. This means that the viral infection cannot spread from the site of inoculation.
- a second feature of the invention of WO92/05263 is a cell which provides the virus with the product of the deleted gene, thus making it possible to grow the virus in tissue culture.
- the virus lacks a gene encoding an essential protein, if it is grown in the appropriate host cell, it will multiply and produce complete virus particles which are to outward appearances indistinguishable from the original virus.
- This mutant virus preparation is inactive in the sense that it has a defective genome and cannot produce infectious virus in a normal host, and so may be administered safely in the quantity required to generate directly a humoral response in the host.
- the mutant virus need not be infectious for the cells of the host to be protected and merely operates in much the same way as a conventional killed or attenuated virus vaccine.
- the immunising virus is itself still infectious, in the sense that it can bind to a cell, enter it, and initiate the viral replication cycle and is therefore capable of initiating an infection within a host cell of the species to be protected, and producing therein some virus antigen.
- the immunising virus is itself still infectious, in the sense that it can bind to a cell, enter it, and initiate the viral replication cycle and is therefore capable of initiating an infection within a host cell of the species to be protected, and producing therein some virus antigen.
- WO92/05263 provided in vivo data which showed that intra-epithelial vaccination of mice via the ear with a mutant form (as described above) of HSV-1 gave better protection against later challenge with wild-type HSV-1, than similar vaccination with killed HSV-1.
- a clear protective effect against the establishment of latent infection in the cervical ganglia was also shown for vaccination with the mutant HSV-1.
- mice with DISC HSV-2 provided better protection against replication of the challenge virus w.t. HSV-2 than inactivated DISC HSV-2.
- the present invention provides a pharmaceutical mutant which comprises a mutant non-retroviral virus whose genome is defective in respect of a gene essential for the production of infectious virus such that the virus can infect normal cells and undergo replication and expression of viral antigen genes in those cells but cannot produce normal infectious virus, for prophylactic or therapeutic use in generating an immune response in a subject infected therewith.
- the defect mdy allow the production and release from the cells of non-infectious viral particles.
- the present invention provides a pharmaceutical which comprises a mutant non-retroviral virus whose genome is defective in respect of a gene essential for the production of infectious virus such that the virus can infect normal cells and replicate therein to give rise to the production and release from the cells of non-infectious viral particles.
- the pharmaceutical may be a vaccine capable of protecting a patient immunised therewith against infection or the consequences of infection by a non-retroviral virus.
- the pharmaceutical may be a vaccine capable of protecting a patient immunised therewith against infection or the consequences of infection by the corresponding wild-type virus.
- the pharmaceutical may be a therapeutic capable of treating a patient with an established non-retiroviral virus infection.
- the pharmaceutical may be a therapeutic capable of treating a patient with an infection established by the corresponding wild-type virus.
- the pharmaceutical may be sub-cutaneously, intra ⁇ muscularly, intra-dermally, epithelially-, (with or without scarification), nasally-, vaginally-, or orally- administrable comprising excipients suitable for the selected administration route.
- the mutant may be from a double-stranded DNA virus.
- the mutant may be from a herpes virus.
- the mutant may be from a herpes simplex virus (HSV).
- the mutant may be a type-1 HSV or a type-2 HSV.
- the defect may be in the glycoprotein gH gene.
- the present invention provides a type-2 HSV whose genome is defective in respect of a gene essential for the production of infectious HSV-2 such that the virus can infect normal cells and undergo replication and expression of viral antigens in those cells but cannot produce normal infectious virus, for prophylactic or therapeutic use in generating an immune response in a subject infected with HSV eg HSV-2.
- the mutant HSV-2 defect allows the production and release from the cells of non-infectious virus particles. Also provided is a type-2 HSV whose genome is defective in respect of a gene essential for the production of infectious HSV-2 such that the virus can infect normal cells and replicate therein to give rise to the production and release from the cells of non-infectious viral particles.
- the mutant may be capable of protecting a patient immunised therewith against infection or the consequences of infection with HSV eg infection by the corresponding wild-type virus.
- the mutant may be capable of treating a patient with an established HSV infection eg infection by the corresponding wild-type virus.
- the defect may be in the glycoprotein gH gene.
- the present invention also provides use of a mutant type-1 HSV whose genome is defective in respect of a gene essential for the production of HSV-1 such that the virus can infect normal cells and undergo replication and expression of viral antigen genes in those cells but cannot produce normal infectious virus, for preparation of a pharmaceutical for prophylactic or therapeutic use in generating an immune response in a subject against type-2 HSV infection.
- the use may be in respect of pharmaceuticals for intra-epithelial (with or without scarification), intra- vaginal, intra-nasal or per-oral administration.
- the present invention also provides an assembly comprising a pharmaceutical (for prophylaxis ie a vaccine or for therapy ie a therapeutic) as described above in a container preferably a pre-filled syringe or glass vial/ampoule with printed instructions on or accompanying the container concerning the administration of the pharmaceutical to a patient to prevent or treat conditions caused by HSV infection.
- the printed instructions may concern the prevention or treatment of facial or genital lesions.
- Vaccines containing the mutants as described can be prepared in accordance with methods well known in the art wherein the mutant is combined in admixture with a suitable vehicle.
- suitable vehicles include, for example, saline solutions, or other additives recognised in the art for use in compositions applied to prevent viral infections.
- Such vaccines will contain an effective amount of the mutant as hereby provided and a suitable amount of vehicle in order to prepare a vaccine useful for effective administration to the host.
- Dosage rates can be determined according to known methods. For example, dosage rate may be determined by measuring the optimum amount of antibodies directed against a mutant resulting from administration of varying amounts of the mutant in vaccine preparations. Attention is directed to New Trends and Developments in Vaccines,
- Therapeutics comprising a mutant as herein provided can be formulated according to known methods to provide therapeutically useful compositions, whereby the mutant is combined in admixture with a pharmaceutically acceptable carrier vehicle.
- a pharmaceutically acceptable carrier vehicle Suitable vehicles and their formulation are described in Remington's Pharmaceutical Science by E. W. Martin.
- Such compositions will contain an effective amount of the mutant hereof together with a suitable amount of carrier vehicle in order to prepare therapeutically acceptable compositions suitable for effective administration to the host.
- vaccines are prepared as injectables,
- the active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, trehalose, or the like and combinations thereof.
- the vaccine may contain minor amounts of auxiliary substances such as other stabilisers and/or pH buffering agents, which enhance the stability and thus the effectiveness of the vaccine.
- the vaccines may be administered parenterally, by injection, for example, subcutaneously, intraepithelially (with or without scarification). Additional formulations which are suitable for other modes of administration eg oral, vaginal and nasal formulations are also provided.
- Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of trehalose mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.
- the compositions may take the form of solutions, suspensions, tablets, pills, capsules sustained release formulations or powders.
- the vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically effective.
- the quantity to be administered will have been predetermined from preclinical and clinical ( phase I ) studies to provide the optimum immunological response.
- the vaccine may be given in a single dose schedule, or preferably in a multiple dose schedule.
- a multiple dose schedule is one in which a primary course of vaccination may be with 1-3 separate doses, followed by other doses given at subsequent time intervals required to maintain and or re-enforce the immune response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months.
- the dosage regimen will also, have been determined from preclinical and clinical studies as maintaining the optimum immunological response over time.
- Figure 1 illustrates the DISC virus concept.
- Figure 2 shows clearance of wild-type HSV-1 (w.t. HSV- 1) strain SCI6 virus in the ears of mice vaccinated with either live DISC HSV-1 or inactivated ( ⁇ -propiolactone treated) w.t. HSV-1 (strain SC16). Groups of 4 mice were vaccinated at the doses indicated by scarification of the left ear pinna. Mice were challenged 14 days post- vaccination with 2x10° pfu w.t. HSV-1 strain SC16 in the right ear pinna and virus titres were measured 5 days post challenge. Data are expressed as the geometric means and standard errors of the means.
- Figure 3 shows measurement of titres of neutralising and ELISA antibody to w.t. HSV-1 in mice vaccinated with either w.t. HSV-1 (strain SC16), live DISC HSV-1, killed DISC HSV-1 or PBS. Sera from mice were assayed in the presence of complement for neutralising antibodies to w.t. HSV-1 in a plaque reduction assay. Individual titres are expressed as the reciprocal dilution of sera required to neutralise 50% of the infectivity obtained in the absence of antibody.
- FIG. 4 shows delayed-type hypersensitivity (DTH) responses in mice vaccinated with either w.t. HSV-1 (strain SC16), live DISC HSV-1, killed DISC HSV-1 or PBS.
- Mice were vaccinated in the left ear pinna at the doses indicated 14 days prior to challenge with 10 6 pfu w.t. HSV-1 (strain SC16) in the opposite ear.
- Ear thickness was measured 24 and 48 hours post-challenge and is expressed as the difference between the challenged and vaccinated ear. Data are presented as the means of differences in ear thickness (in ⁇ m) .
- FIG. 5 shows cytotoxic T cell (CTL) responses in mice vaccinated with either live DISC HSV-1, killed DISC HSV-1, MDK (a thymidine kinase negative HSV-1 strain) or PBS.
- CTL cytotoxic T cell
- Mice were immunised twice intraperitoneally three weeks apart and cell suspensions made from spleens 10 days after the second injection. Cells were stimulated in vitro for 4 days before being tested in a CTL assay using 51 Cr- labelled A20/2J as target cells. Data are presented as mean % 51 Cr release from quadruplicate samples at each point. Standard errors of the means are all ⁇ 10%.
- Figure 6 shows clinical symptoms as assessed by erythema score in guinea-pigs post challenge with 10 52 pfu w.t. HSV-2 (strain MS) subsequent to vaccination with doses of 2 x 10 7 pfu DISC HSV-1 at a 3 week interval either by the intra-epithelial or the intra-vaginal route;
- Figure 7 shows clinical symptoms as assessed by total lesion score in guinea-pigs post challenge with 10 5,2 pfu w.t. HSV-2 (strain MS) subsequent to vaccination with doses of 2 x 10 7 pfu DISC HSV-1 at a 3 week interval either by the intra-epithelial or the intra-vaginal route.
- Figure 8 shows post challenge virus w.t. HSV-2 (strain MS) subsequent to vaccination with doses of 2 x 10 7 pfu DISC HSV-1 at a 3 week interval either by the intra-epithelial or the intra-vaginal route.
- Figure 8 shows post
- FIG. 9a shows recurrent disease as the cumulative mean erythema index per animal.
- Fig. 9b shows recurrent disease as cumulative mean number of days with disease per animal.
- Figure 10 shows mean lesion score per animal (guinea- pigs) with w.t. HSV-2 (strain MS) infection and which have been vaccinated via the vaginal, oral or nasal routes with a mock virus preparation, DISC HSV-1 or inactivated DISC HSV-1.
- Figure 11 shows mean erythema score per animal (guinea-pigs) with w.t. HSV-2 (strain MS) infection and which have been vaccinated via the vaginal, oral or nasal routes with a mock virus preparation, DISC HSV-1 or inactivated DISC HSV-1.
- Figure 12 shows the mean log titre of w.t. HSV-2
- strain MS per animal (guinea-pigs) with w.t. HSV-2 (strain MS) infection and which have been vaccinated via the vaginal, oral or nasal routes with a mock virus preparation, DISC HSV-1 or inactivated DISC HSV-1.
- Figure 13 shows recurrent disease following therapeutic vaccination. This is shown as mean cumulative number of days on which disease was observed (disease/days) in groups of guinea-pigs vaccinated with DISC HSV-1 either intra-epithelially or intra-vaginally or with a mock virus preparation intra-vaginally after challenge with w.t. HSV-2 (strain MS). Disease was classified as either presence of one or more lesions or an erythema score of 1 or more.
- Animals were monitored from 4 weeks after initial challenge with w.t. HSV-2 (strain MS) (day o) for 100 days. Animals were vaccinated at Day 0, Day 24 and Day 44 with 2 x 10 7 pfu or equivalent dose as indicated.
- Figure 14 relates to the long-term protective effect in mice of vaccination with DISC HSV-1 against challenge with w.t. HSV-1 (strain SC16).
- the graph shows the mean log titre of w.t. HSV-1 in the ears 5 days post challenge and 223 days post vaccination.
- Figure 15 relates to the long-term protective effect in mice of vaccination with DISC HSV-1 against challenge with w.t. HSV-1 (strain SC16).
- the graph shows neutralising antibody titres days 15, 27, 90, 152 and 218 post vaccination as stated.
- Figure 16 relates to the protective effect in mice of vaccination with DISC HSV-2 against challenge with w.t.
- HSV-2 (strain HG52 ) for vaccinations with live DISC HSV-2, killed DISC HSV-2 and w.t. HSV-2 (strain HG52) at varying doses
- the graph shows mean log titre of w.t. HSV-2 in the ear post challenge.
- Figure 17 illustrates the construction of a single plas id containing the complete HSV-2 gH gene.
- Figure 18 shows the sequence of HSV-2 strain 25766 in the region of the gH gene including a translation of the gH gene in single letter amino acid code.
- Figure 19 shows a comparison of the DNA sequence of
- HSV-1 and HSV-2 strain 25766 in the region of the gH gene are HSV-1 and HSV-2 strain 25766 in the region of the gH gene.
- Figure 20 shows a comparison of the deduced amino acid sequences of the HSV-1 strain 17 and HSV-2 strain 25766 gH proteins.
- Figure 21 shows graphically the level of similarity between the DNA sequences of HSV-1 and HSV-2 in the region of the gH gene (from U GCG program Plotsimilarity) .
- Figure 22 shows graphically the level of similarity between the amino acid sequences of the HSV-1 and HSV-2 gH proteins (from UWGCG program Plotsimilarity).
- Figure 23 shows the construction of pIMMB26; two fragments from the left and right sides of the HSV2 gH gene were amplified by PCR and cloned into pUC119. The four oligonucleotides MB57, MB58, MB59 and MB60 are shown.
- Figure 24 shows the construction of pIMMB45.
- Figure 25 shows construction of the first stage recombination vector pIMMB47+.
- Figure 26 shows construction of the second stage recombination vector pIMMB46.
- Figure 27 shows a restriction map analysis for recombinants HG52-D, TK minus DISC virus, TK plus DISC virus.
- Figure 28 shows Southern blots of BamHI digestions of various viruses, probed with the right-hand flanking sequence as shown in Fig. 27. Lane 5: HG52-D virus, lane 2: TK-minus "first stage” DISC virus and lanes 3, 4, 6, 7 and 8: TK-plus "second stage” DISC viruses.
- Herpes Simplex Virus Deleted in Glycoprotein H (qH-HSV)
- Herpes simplex virus is a large DNA virus which causes a wide range of pathogenic symptoms in man, including recurrent facial and genital lesions', and a rare though often fatal encephalitis. In general, it seems that type 1 HSV (HSV-1) seems to be particularly associated with facial lesions, whilst type 2 HSV (HSV-2) seems to be particularly associated with genital lesions. To some extent infection with HSV can be controlled by chemotherapy using the drug Acyclovir, but as yet there is no vaccine available to prevent primary infection or the consequences of this infection. Thus there is a need both for better therapeutics to treat established HSV infections and for prophylactics to prevent the establishment of HSV infection and/or its associated pathology.
- a difficulty with vaccination against HSV is that the virus generally spreads within the body by direct transfer from cell to cell. Thus humoral immunity is unlikely to be effective, since circulating antibody can only neutralise extracellular virus. Of more importance for the control of virus infection, is cellular immunity, and so a vaccine which is capable of generating both humoral and cellular immunity, but which is also safe, would be a considerable advantage.
- a suitable target gene for inactivation within the HSV genome is the glycoprotein H gene (gH) .
- the gH protein is a glycoprotein which is present on the surface of the virus envelope. This protein is thought to be involved in the process of membrane fusion during entry of the virus into the infected cell. This is because temperature sensitive virus mutants with a lesion in this gene are not excreted from virus infected cells at the non-permissive temperature (Desai et al. , J. Gen. Virol. 69, 1147-1156, 1988). The protein is expressed late in infection, and so in its absence, a considerable amount of virus protein synthesis may still occur.
- HSV2 Herpes Simplex type 2
- pTW49 is the BamHl R fragment of
- pTW54 is the BamHl S Fragment of HSV2 strain 25766 cloned into pBR322.
- the construction of a single plasmid containing the complete gH gene is shown in Figure 17.
- pTW49 was digested with BamHl and Sail, and an 870 base pair (bp) fragment isolated from an agarose gel.
- pTW54 was digested with BamHl and Kpnl and a 2620bp fragment isolated from an agarose gel. The two fragments were ligated together with the plasmid pUC119 cut with Sail and Kpnl, resulting in the plasmid pIMMB24.
- pIMMB24 was digested with Sail and Kpnl.
- the plasmid was digested with Dral (which cuts in the vector sequences), to aid in isolation of the 3490bp insert.
- the 3490bp insert containing the HSV2 sequences was purified from an agarose gel. It was then sonicated, the ends repaired using T4 DNA polymerase and Klenow, and size fractionated on an agarose gel. A fraction containing DNA molecules of approximately 300-600bp in length was ligated into M13mpll cut with S al (Amersham International UK). The ligated mixture was transformed into E.coli strain TGI, and individual plaques were picked. Single- stranded DNA was made from each plaque picked, -and was sequenced using the dideoxy method of sequencing, either with Klenow enzyme or with Sequenase, and using 35 S dATP.
- sequence data was also obtained by sequencing directly from the pIMMB24 plasmid using oligonucleotide primers designed from sequence already obtained. In order to obtain sequence from regions flanking the gH gene, some sequence information was also obtained from the plasmid pTW49. Because of the high G+C ratio of HSV2 DNA, there were several sequence interpretation problems due to 'compressions' on the gels. These have yet to be resolved. In a small number of places therefore, the present sequence represents the best guess as to what the correct sequence is, based on comparisons with the previously published HSVl sequence.
- Oligonucleotides MB57, MB58, MB59 and MB75 were designed to isolate and clone the regions of sequence flanking the HSV2 gH gene. As shown in Figure 23, the oligonucleotides were used in a polymerase chain reaction (PCR) to amplify fragments of DNA from either side of the gene. Restriction sites were included in the oligonucleotides so that the resultant fragments contained these sites at their ends, enabled cloning of the fragments into a suitably cut plasmid. The following oligonucleotides, based on the HSV2 sequence, were used for this purpose:
- such a plasmid allows the skilled person to produce a defective HSV-2 virus lacking precisely the sequences for the gH gene (see below). If these same sequences are cloned into a suitable cell carrying a copy of the gH gene deleted from the HSV-2 genome, this 'complementing cell' can then support the growth of the defective HSV-2 virus by providing the gH protein. Because the sequences have been chosen so that there is no overlap between the sequences in the cell and the sequences in the virus, the possibility of the virus acquiring the gene from the cell by recombination is virtually eliminated.
- HSV-1 gH gene F6 cells, Forrester et al, Journal of Virology, 1992, 66, p. 341-348
- F6 cells Forrester et al, Journal of Virology, 1992, 66, p. 341-348
- CR1 cells use the same promoter and gH gene as F6 cells, but the sequences downstream of the gene are truncated so that there is no overlap of sequences between the final DISC virus and the cell line. This is very useful since it means that homologous recombination cannot occur between the DISC virus and the cell line DNA.
- wild-type gH-plus viruses occur by recombination at about 1 in 10 b viruses.
- Another cell line, CR2 was also made, which expresses the gH gene from the HSV-2 strain 25766. This also supports the growth of a DISC HSV-2 and also has no overlapping sequences between the virus and the cell.
- Viral DNA is purified from virus by standard methods. Flanking sequences to either side of the gH gene are amplified by PCR using Vent DNA polymerase (New England Biolabs ) which has a lower error rate than Taq DNA polymerase (see Fig. 24).
- the oligonucleotides used for PCR include restriction site recognition sequences, as well as the specific viral sequences (see below).
- Two vectors are made, one for the first stage and one for the second stage of recombination. For both vectors the right hand flanking sequences start at the same position to the right of the gH gene.
- the first stage vector has left hand flanking sequences that, in addition to deleting the HSV-2 gH gene, also delete the 3' portion of the viral TK gene.
- the second stage vector has left hand flanking sequences which restor the complete TK gene, and extend right up to the 5' end of the gH gene, as desired in the final virus.
- oligonucleotides used are as follows:
- the first stage recombination vector, pIMMB47+ The two PCR fragments made by oligos MB97-MB96 and by oligos MB57-MB58 are digested with the restriction enzymes appropriate to the sites that have been included in the PCR oligonucleotides.
- the MB97-MB96 fragment is digested with Hindlll and Hpal.
- the MB57-MB58 fragment is digested with Hpal and EcoRI. These fragments are then ligated into the vector pUC119 which has been digested with Hindlll and EcoRI.
- the resultant plasmid is called pIMMB45 (see Fig. 24).
- the E.coli beta-galactosidase gene under the control of the Cytomegalovirus (CMV) immediate early promoter is inserted into pIMMB45.
- CMV Cytomegalovirus
- the CMV promoter plus beta-galactosidase gene is excised from a suitable plasmid carrying the promoter and gene using one or mote appropriate restriction enzymes. If necessary, the ends are filled in using the Klenow fragment of DNA polymerase. This is the approach taken by the present applicants. However alternative methodologies will be apparent to those skilled in the art.
- the beta-galactosidase gene may be under the control of the SV40 promoter, in which case, the gene and promoter can be excised from the plasmid pCHHO (Pharmacia PL Biochemicals ) using BamHl and Tthllll, and the ends are filled in using the Klenow fragment of DNA polymerase ( Ecob-Prince, M.S., et al 1993 J. Gen. Virol, 74, p. 985-994). The fragment is gel- purified.
- the plasmid pIMMB45 is digested with Hpal, phosphatased with Calf Intestinal Alkaline Phosphatase (CIAP) to abolish self ligation, and gel-purified. The gel-purified fragments are then ligated together to produce the plasmid pIMMB47+ (see Fig. 25).
- the second stage recombination vector, pIMMB46 The two PCR fragments made by oligos MB94-MB109 and by oligos MB57-MB108 are digested with the restriction enzymes appropriate to the sites that have been included in the PCR oligonucleotides.
- the MB94-MB109 fragment is digested with Hindlll and Hpal.
- the MB57-MB108 fragment is digested with Hpal and EcoRI. These fragments are then ligated into the vector pUC119 which has been digested with Hindlll and
- the resultant plasmid is called pIIMB46 (see Fig. 26).
- the oligonucleotides used are as follows:
- Virus DNA was made from strain HG52-D, which is a plaque-purified isolate of the HSV-2 strain HG52.
- Virus DNA (2.5 ⁇ g) and pIMMB47+ plasmid DNA (0.25 ⁇ g ) was transtected into CR1 cells u ing the CuP0 precipitation method (Chen & Okayama, Molecular and Cellular Biology, 7, p. 2745). Recombination takes place within the cells, and a mixture of recombinant and wild type virus is produced. The mixture was plaque-purified three times on CRl cells in the presence of acyclovir ( 10 ⁇ g/ml ) , to select for TK- minus virus. A single plaque was then grown up and analysed.
- the virus was titrated on normal Vero cells and on CRl cells. If the virus is a gH-deleted virus, it should only grow on CRl cells and not on Vero cells. Table 1 shows that this is the case. It can be seen that the virus does not grow at all on the non-complementing Vero cells even at the highest virus concentrations, but does grow well on the CRl complementing cell line, which expresses the HSV-1 gH gene. The virus also grows well on CR2 cells which express the HSV-2 gH gene (data not shown).
- Table 1 growth of first stage recombinant virus on complementing (CRl) and non-complementing (Vero) cells.
- TK-minus DISC virus DNA was made from this TK-minus DISC virus and a recombination was carried out as above with the plasmid pIMMB46.
- TK-plus recombinants were selected, on a gH-expressing TK-minus BHK cell line, by growth in medium containing ⁇ iethotrexate, thymidine, glycine, adenosine and guanosine.
- Virus was harvested and grown again under selective conditions twice more before a final plaque purification was carried out on CRl. Virus was grown up and analysed by Southern blotting.
- Virus DNA from the original HG52-D, the TK-minus DISC virus, and the TK- plus DISC virus were digested with BamHl and separated on an agarose gel. The DNA bands were then transferred to nylon membrane by the Southern blotting method, and probed with radiolabelled fragments from the right hand flanking sequences.
- Fig. 27 shows the structures of these viruses, with the expected band sizes after BamHl digestion. The probe used is marked as 'R' beneath a dashed line. The probe should hybridise to a different size band in each of these viruses, as follows:
- Fig. 28 shows that this is the case.
- Lane 5 shows the HG52-D virus
- Lane 2 contains the TK-minus "first stage” DISC virus
- lanes 3, 4, 6, 7 and 8 contain TK-plus "second stage” DISC viruses. This confirms that the DNA structure in each of these viruses is as expected.
- the present application refers to certain strains of HSV-1 and HSV-2. It is not necessary that the general teaching contained herein is put into effect with precisely the mentioned strains. Strains of HSV-1 and HSV-2 having high sequence homology to one another by which the invention may be put into effect are readily available. For example, one source of HSV is the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 USA. The following are available from ATCC under the indicated accession numbers.
- ATCC American Type Culture Collection
- mice 4-5 week old BALB/c mice were vaccinated with varying doses of DISC HSV-1 or inactivated virus by scarification in the left ear pinna. Virus was inactivated using ⁇ - propiolactone (for further details see WO92/05263 published on 2 April 1992 and incorporated herein by reference).
- the mice were challenged with 2 x 10 6 pfu w.t. HSV-1 (strain SC16) in the opposite ear two weeks after vaccination. The amount of virus present in that ear 5 days post challenge was assayed by plaquing on BHK cells. (See Fig. 2. )
- mice were vaccinated with 5xl0 5 pfu of DISC HSV-1, killed DISC HSV-1, w.t. HSV-1 (strain SC16) or with PBS and serum samples taken at 2 and 14 weeks post vaccination.
- Neutralising antibodies were measured in the presence of complement and expressed as the inverse of the serum dilution which reduced the number of plaques by 50%.
- ELISA antibody titres were measured on plates coated with HSV-1 infected BHK cell lysates and titrated to endpoint. ( See Fig. 3. ) It can be seen from Fig. 3 that no significant differences in antibody titres were observed between animals vaccinated with DISC HSV-1 and an equivalent amount of killed DISC HSV-1.
- the importance of a DTH response in protection against herpes virus infection has been well documented.
- the ability of the DISC HSV-1 to raise a DTH response was investigated by vaccinating groups of mice with DISC HSV-1, killed DISC HSV-1, and live w.t. HSV-1, by scarification of the left ear pinna.
- the DTH responses induced by different doses of the various vaccine preparations thus correlate with their protective effect against challenge virus replication.
- the efficacy of vaccination with low doses of the DISC HSV-1 vaccine may therefore be due to the induction of T cell- mediated immunity.
- Cytotoxic T cells have been shown to be involved in the protection against, and recovery from, primary HSV infection.
- DISC HSV-1 vaccinated mice were therefore studied for the presence of HSV-1 specific cytotoxic T cell activity.
- Cytotoxic T cell activity following immunisation was generated and assayed according to standard procedures eg as exemplified in Martin, S. et al, 1988, J. Virol. 62:
- mice 2265-2273 and Gallichan, W.S. et al, J. Infect. Dis. 168: 633-629. More specifically, groups of female BALB/c mice were immunised intra-peritoneally with 2 x 10 7 pfu of virus (DISC HSV-1; killed DISC HSV-1; MDK a thymidinfe kinase negative HSV-1 strain) on day 0 and the immunisations repeated (same dose and route) after 3 weeks. A group of control mice received 0.1ml of PBS intraperitoneally at the same time points. Ten days after the second immunisation the spleens of the mice were removed and pooled for each group.
- DISC HSV-1 killed DISC HSV-1
- MDK a thymidinfe kinase negative HSV-1 strain
- Spleens were also removed from unim unised BALB/c mice for the preparation of feeder cells ( 16 feeder spleens being sufficient for 4 groups of six effector spleens). All subsequent steps were performed in a laminar flow hood using aseptic technique.
- the spleens were passed through a sterile tea-strainer to produce a single cell suspension in RPMI 1640 medium supplemented with 10% heat inactivated foetal calf serum (effector medium). Debris was allowed to settle and the single cell suspension was transferred to a fresh container.
- the cell suspensions were washed twice in effector medium (1100 rpm, 10 minutes) and then passed through sterile gauze to remove all clumps. The effector spleen cell suspensions were then stored on ice until required.
- Feeder spleen cells were resuspended to 1 x 10 7 cells/ml in effector medium and mitomycin C was added to a final concentration of 20 ⁇ g/ml. The feeder cells were incubated at 37 ⁇ C for 1 hour. Feeder cells were washed four-times in PBS supplemented with 1% FCS and once in PBS with no protein. Live virus ( DK) was added to the mitomycin C treated feeder cell pellet at a concentration of 3 pfu of virus per spleen cell. Following a one hour incubation at 37°C the feeder cells were washed once with effector cell medium.
- DK Live virus
- Effector cells were resuspended to 5 x 10 6 cells/ml, whilst feeder cells were resuspended to 2.5 x 10 6 cells/ml.
- 500 ⁇ l of effector cell suspension and 500 ⁇ l feeder cell suspension were added to the wells of a 24 well plate. The plates were incubated in a humid atmosphere at 37°C (5% C0 2 ) for 4 days.
- the effector and feeder cells were harvested from the 24 well plate.
- the cells were spun down once and the pellet resuspended in effector medium ( 5ml of medium per 2 plates ) .
- the cell suspension was layered onto lymphocyte separation medium and spun at 2500rpm for 20 minutes.
- the live effector cells were harvested from the interface and washed twice, once at 1500 rpm for 15 minutes and once at 1100 rpm for 10 minutes.
- the effector cells were finally resuspended at the required concentration in effector medium and stored on ice until required.
- Uninfected syngeneic A202J target cells A20/2J cells were harvested from tissue culture flasks; 2 x 10 7 cells were added to each of 2 containers (to become infected and uninfected targets ) . The cells were washed with DMEM (with no additions) . To the infected cells live MDK virus was added at lOpfu per cell and an equivalent volume of EMEM was added to the uninfected cells. One mCi of 51Cr was added to each of the universals and the cells were incubated at 37 ⁇ C (in a waterbath) for 1 hour. The target cells were then washed three times (10 minutes, llOOrpm) in target medium (DMEM supplemented with 10% FCS ) and finally resuspended to the required cell concentration in target cell medium.
- target medium DMEM supplemented with 10% FCS
- Both uninfected and infected target cells were resuspended to 1 x 10° cells/ml and 1 x 10 b cells/ml and lOO ⁇ l ( ie to give 1 x 10 s targets/well and 1 x 10 4 targets/well respectively) was plated out into the appropriate wells of a round bottomed 96 well plate. All experimental points were set up in quadruplicate. Each effector cell type was resuspended to 8 x 10 fa cells/ml in effector medium and two-fold dilutions were prepared.
- effector to target ratios were: 8:1, 4:1, 2:1 and 1:1.
- effector to target ratios were 80:1, 40:1, 20:1 and 10:1.
- Maximum chromium release for each target cell type was obtained by adding lOO ⁇ l of 20% Triton X-100 to wells containing target cells only ( ie no effectors).
- the spontaneous release for each target cell type was obtained by the addition of lOO ⁇ l effector cell medium to wells containing target cells only.
- the plates were incubated at 37 ⁇ C for four hours in a humid atmosphere. After this time the plates were spun for four minutes at 1500rpm and lOO ⁇ l of supernatant was removed from each of the wells. The supernatant was transferred to LP2 tubes and radioactivity contained in the tubes was then counted for 1 minute on a gamma' counter. The % specific chromium release was determined using the formula
- HSV-1 specific CTL activity comparable to that produced by infection with the fully replicative MDK virus.
- HSV-1 specific CTL activity was observed in mice immunised with killed DISC HSV-1 or in PBS treated animals, although some non ⁇ specific killing was observed in these animals. The reason for this is not clear, but it could represent a high level of NK cell activity.
- Vaccination of mice with the DISC HSV-1 has thus been shown to induce antibody, CTL and DTH activity against HSV- 1 virus antigens.
- the ability to activate both humoral and cell-mediated immune responses against a broad spectrum of virus proteins may explain the effectiveness of the DISC virus vaccination. LONG-TERM PROTECTION
- the in vivo mouse ear model was used to study long term prophylactic effect of DISC HSV-1
- mice 4-5 week old BALB/c mice were divided into groups containing 6 animals each. The groups were vaccinated as follows:
- Fig. 15 shows the neutralising antibody titres induced by the various vaccinations. This shows that since 2 doses of DISC HSV-1 produce the same titre as two doses of the inactivated DISC HSV-1, the protective effect of DISC HSV-1 cannot be simply explained by antibody induction.
- PROPHYLACTIC EFFECT OF DISC HSV-2 The in vivo mouse ear model was used to study the prophylactic effect of DISC HSV-2.
- mice Six week old BALB/c mice were divided into groups. They were immunised by scarification of the left ear pinna as follows. Group Vaccination Material and Dose
- the DISC HSV-2 was a gH deletion mutant of strain HG52 Three weeks later, all groups were challenged by scarification of the right ear pinna with 5 x 10 4 of w.t. HSV-2 (strain HG52 ) .
- the amount of virus present in the challenged ear (right) 5 days post challenge was assayed by plaquing on BHK cells (see Fig. 16).
- the results as depicted by the figure show that vaccination with DISC HSV-2 at doses of 5 x 10 3 , 5 x 10 4 and 5 x 10 5 pfu provides good protection against challenge with w.t. HSV-2 (strain HG52 ) compared to killed DISC HSV-2.
- better protection was obtained with w.t. HSV-2 at doses of 5 x 10 4 and 5 x lO 5 pfu, but the use of normal live wild type viruses as vaccines is undesirable.
- HSV-2 appears to be closely associated with genital lesions.
- the guinea pig currently provides the best animal model for primary and recurrent genital disease in humans (Stanberry, L.R. et al. J. Inf. Dis. 1982, 146, 397-404). Therefore the applicants have extended the earlier described mouse studies to the guinea pig vaginal model of HSV-2 infection which provides a useful system to assess the i munogenicity of candidate vaccines against genital HSV-2 infection in humans. It permits a comprehensive assessment of primary clinical symptoms following intra- vaginal challenge with HSV-2, and also analysis of the frequency of subsequent recurrences.
- a control group of 21 animals was vaccinated intra-vaginally with a mock virus preparation and a further group of 14 animals was vaccinated intra-epithelially with two equivalent doses of ⁇ -propiolactone-inactivated w.t. HSV-1.
- Vaccinated animals were challenged 3 weeks later with 10 5*2 pfu w.t. HSV-2 virus (strain MS) and monitored for the symptoms of primary and recurrent disease.
- strain MS pfu w.t. HSV-2 virus
- animals were assessed daily over a two week period for symptoms of primary infection.
- Clinical lesions were scored as a direct numerical value, and erythema was scored on a scale of 1-5.
- the vaginal area was also measured as an index of oedema (data not shown). The results are shown in Figs. 6 and 7. Points on the graphs represent mean erythema score per animal per day (Fig. 6) and mean total lesion score per day per animal (Fig. 7).
- DISC HSV-1 was propagated on Vero cells ( F6 ) which had been transfected with the HSV-1 gH gene as described previously in WO92/05263 published on 2 April 1992.
- F6 cells confluent monolayers of F6 cells were infected with DISC HSV-1 at a multiplicity of 0.1 pfu per cell and harvested when 90-100% cpe was observed.
- Cells were harvested with a cell scraper, pelleted by centrifugation and the pellet resuspended in a small volume of Eagles Minimum Essential Medium (EMEM). The suspension was sonicated for 1 minute and stored in aliquots at -70°C. Virus titres were determined on F6 cells.
- EMEM Eagles Minimum Essential Medium
- DISC HSV-1 was inactivated by the addition of ⁇ - propiolactone at a concentration of 0.05% for one hour at room temperature. Inactivation was checked by adding the virus to F6 cells.
- HSV-2 strain MS was propagated and titred on
- Groups of 12 animals were immunised with two doses of 8 x 10 6 pfu DISC HSV-1 or with equivalent doses of inactivated DISC HSV-1, on days 1 and 17 of the experiment. Immunisation was performed with either 0.05 ml of virus intravaginally, with 0.2 ml of virus intranasally or with 0.2 ml virus orally. A control group of 12 animals was vaccinated intravaginally with a mock preparation of virus consisting of sonicated Vero cells. All groups were challenged intravaginally on day 34 with 10 5*2 pfu HSV-2 ( strain MS ) and the experiment blinded by randomisation of the cages by an independent worker.
- the mean lesion score per animal, the mean erythema score and the effect of vaccination on post challenge virus replication for each of the immunisation groups are shown in Figs 10, 11 and 12 respectively.
- vaccination with DISC HSV-1 by the intravaginal route provided a high degree of protection from primary symptoms of infection.
- vaccination with inactivated DISC HSV-1 at an equivalent dose did not lead to any significant protection.
- Intranasal immunisation with DISC HSV-1 resulted in an even higher degree of protection than intravaginal vaccination. This was particularly apparent when looking at the number of days with severe disease, as defined by a lesion score of 6 or more (see table 2). Inactivated DISC HSV-1 gave some protection via the intranasal route, but it was not as effective as vaccination with DISC HSV-1.
- Vaccination via the oral route also led to protection, but to a lesser degree than intranasal or intravaginal vaccination. Again vaccination with DISC HSV-1 virus protected more efficiently than vaccination with inactivated DISC HSV-1.
- Intravaginal vaccination with inactivated virus resulted in clinical disease symptoms similar to those observed in mock-infected guinea-pigs.
- Intranasal vaccination with inactivated DISC HSV-1 gave a significant degree of protection, but not as high as
- Sera were collected from these animals at the end of the 100 day observation period.
- the ELISA and NT antibody titres in the sera were not significantly higher than those recorded post-challenge but before therapeutic treatment and there were no significant differences in titres between the mock-treatment group and the DISC HSV-1 treated groups.
- Days 1-13 covers the period between the two treatments.
- Days 14-27 covers the two week period subsequent to the second treatment.
- Days 1-27 covers the complete period.
- treatment with DISC HSV-2 was effective in alleviating symptoms caused by infection with HSV-2 strain MS.
- Treatment with DISC HSV-2 was more effective than treatment with DISC HSV- 1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939305710A GB9305710D0 (en) | 1993-03-19 | 1993-03-19 | Viral vaccines |
GB9305710 | 1993-03-19 | ||
GB939324964A GB9324964D0 (en) | 1993-12-06 | 1993-12-06 | Viral vaccines |
GB9324964 | 1993-12-06 | ||
PCT/GB1994/000572 WO1994021807A2 (en) | 1993-03-19 | 1994-03-21 | Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0689603A1 true EP0689603A1 (de) | 1996-01-03 |
Family
ID=26302619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94909990A Withdrawn EP0689603A1 (de) | 1993-03-19 | 1994-03-21 | Defektiver mutanter nicht-retroviraler virus (2.b.hsv) zum impstoff |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0689603A1 (de) |
JP (1) | JPH08507784A (de) |
AU (1) | AU696336B2 (de) |
CA (1) | CA2158148A1 (de) |
WO (1) | WO1994021807A2 (de) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7223411B1 (en) * | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
US5807557A (en) * | 1994-07-25 | 1998-09-15 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex |
US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
GB9423663D0 (en) * | 1994-11-23 | 1995-01-11 | Cantab Pharma Res | Viral preparations, immunogens, and vaccines |
AU711121B2 (en) * | 1995-02-21 | 1999-10-07 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
WO1996029421A1 (en) * | 1995-03-23 | 1996-09-26 | Cantab Pharmaceuticals Research Limited | Vectors for gene delivery |
US6251939B1 (en) | 1995-06-07 | 2001-06-26 | Promega Biosciences, Inc. | Carbamate-based cationic lipids |
US5851826A (en) * | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
JPH11513565A (ja) * | 1995-10-19 | 1999-11-24 | セント ジュード チルドレンズ リサーチ ホスピタル | ヘルペスウィルスベクター及びその利用 |
US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
PL336523A1 (en) | 1997-04-28 | 2000-07-03 | Rhone Poulenc Rorer Sa | Intraneoplastic delivery of an angiogenesis antagonist by means of adenoviruses in order to treat neoplasms |
GB9721909D0 (en) * | 1997-10-17 | 1997-12-17 | Cantab Pharma Res | Gene delivery vectors and their uses |
US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
GB9808922D0 (en) | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
US6225456B1 (en) | 1998-05-07 | 2001-05-01 | University Technololy Corporation | Ras suppressor SUR-5 |
US6506889B1 (en) | 1998-05-19 | 2003-01-14 | University Technology Corporation | Ras suppressor SUR-8 and related compositions and methods |
US6399354B1 (en) | 1998-07-31 | 2002-06-04 | President And Fellows Of Harvard College | Replication-competent virus expressing a detectable fusion protein |
GB9816761D0 (en) | 1998-07-31 | 1998-09-30 | Phogen Limited | Herpesvirus preparations and their uses |
US6441156B1 (en) | 1998-12-30 | 2002-08-27 | The United States Of America As Represented By The Department Of Health And Human Services | Calcium channel compositions and methods of use thereof |
GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
CA2399940A1 (en) | 2000-04-13 | 2001-10-25 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
BR0015875A (pt) | 2000-05-10 | 2003-06-24 | Mayo Foundation | Anticorpos igm humano com a capacidade de induzir remielinização, e usos diagnósticos e terapêutico dos mesmos, particularmente no sistema nervoso central |
DK1317564T3 (da) | 2000-09-14 | 2007-12-03 | Sinai School Medicine | Screeningsfremgangsmåder til at identificere G-proteiner og andre forbindelser, som modulerer phosphodiesterase (PDE)-aktiviteten |
US7060442B2 (en) | 2000-10-30 | 2006-06-13 | Regents Of The University Of Michigan | Modulators on Nod2 signaling |
KR20030074680A (ko) | 2000-12-28 | 2003-09-19 | 와이어쓰 | 스트렙토코커스 뉴모니에 유래 재조합 보호 단백질 |
CA2441476A1 (en) | 2001-03-02 | 2002-09-12 | The Rockefeller University | Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
US7803982B2 (en) | 2001-04-20 | 2010-09-28 | The Mount Sinai School Of Medicine Of New York University | T1R3 transgenic animals, cells and related methods |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
US7432057B2 (en) | 2004-01-30 | 2008-10-07 | Michigan State University | Genetic test for PSE-susceptible turkeys |
US7604798B2 (en) | 2004-07-15 | 2009-10-20 | Northwestern University | Methods and compositions for importing nucleic acids into cell nuclei |
CA2573702C (en) | 2004-07-16 | 2013-10-15 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv |
GB2421025A (en) * | 2004-12-09 | 2006-06-14 | Oxxon Therapeutics Ltd | HSV vaccination vectors |
US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
CN101437539B (zh) | 2005-07-05 | 2013-10-02 | 康奈尔研究基金会(有限公司) | 通过干扰cd99l2阻断白细胞迁出和炎症 |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
US8093043B2 (en) | 2008-06-04 | 2012-01-10 | New York University | β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis |
CN102123732A (zh) | 2008-06-20 | 2011-07-13 | 杜克大学 | 用于引发免疫应答的组合物,方法及试剂盒 |
EP2650014A2 (de) | 2008-06-20 | 2013-10-16 | Wyeth LLC | Zusammensetzungen und Verfahren zur Verwendung von ORF1358 von Beta-hämolytischen Streptokokken-stämmen |
DK2356135T3 (en) | 2008-11-05 | 2017-12-04 | Wyeth Llc | IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE |
WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
AU2011227050B2 (en) | 2010-03-19 | 2016-12-08 | University Of South Alabama | Methods and compositions for the treatment of cancer |
MX350142B (es) | 2010-08-23 | 2017-08-28 | Wyeth Llc * | Formulaciones estables de antigenos rlp2086 de neisseria meningitidis. |
EP3549601B1 (de) | 2010-09-10 | 2021-02-24 | Wyeth LLC | Non-lipidierten varianten von neisseria meningitidis orf2086 antigene |
US9458456B2 (en) | 2011-04-01 | 2016-10-04 | University Of South Alabama | Methods and compositions for the diagnosis, classification, and treatment of cancer |
US9464291B2 (en) | 2012-01-06 | 2016-10-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
MX359256B (es) | 2012-03-09 | 2018-09-19 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
EP2964665B1 (de) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogene fusionspolypeptide |
AU2014249045A1 (en) | 2013-03-11 | 2015-10-29 | University Of Florida Research Foundation, Inc. | Delivery of CARD protein as therapy for occular inflammation |
RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
US9950056B2 (en) | 2013-09-24 | 2018-04-24 | Duke University | Compositions, methods and kits for eliciting an immune response |
US11053291B2 (en) | 2014-02-19 | 2021-07-06 | University Of Florida Research Foundation, Incorporated | Delivery of Nrf2 as therapy for protection against reactive oxygen species |
US10918712B2 (en) | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
CN106456805B (zh) * | 2014-03-03 | 2020-01-10 | 阿尔伯特爱因斯坦医学院公司 | 重组单纯疱疹病毒2(hsv-2)疫苗载体 |
CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
US11306292B2 (en) | 2017-05-15 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
WO2018211419A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3895366B2 (ja) * | 1990-09-25 | 2007-03-22 | キャンタブ ファーマシューティカルズ リサーチ リミティド | ウィルス ワクチン |
TW289731B (de) * | 1992-07-09 | 1996-11-01 | Akzo Nv | |
ATE288483T1 (de) * | 1992-07-30 | 2005-02-15 | Akzo Nobel Nv | Nicht-verbreitendes lebendes herpesvirusvakzin |
-
1994
- 1994-03-21 WO PCT/GB1994/000572 patent/WO1994021807A2/en not_active Application Discontinuation
- 1994-03-21 CA CA002158148A patent/CA2158148A1/en not_active Abandoned
- 1994-03-21 AU AU62617/94A patent/AU696336B2/en not_active Ceased
- 1994-03-21 EP EP94909990A patent/EP0689603A1/de not_active Withdrawn
- 1994-03-21 JP JP6520817A patent/JPH08507784A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9421807A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2158148A1 (en) | 1994-09-29 |
WO1994021807A3 (en) | 1994-12-08 |
AU6261794A (en) | 1994-10-11 |
AU696336B2 (en) | 1998-09-10 |
WO1994021807A2 (en) | 1994-09-29 |
JPH08507784A (ja) | 1996-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU696336B2 (en) | Defective mutant non-retroviral virus (e.g. HSV) as vaccine | |
Boursnell et al. | A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease | |
Morrison et al. | Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection | |
US8501194B2 (en) | Vaccine for viruses that cause persistent or latent infections | |
US6541009B1 (en) | Viral vaccines | |
JP5845191B2 (ja) | 単純ヘルペスウイルスワクチン | |
US8986707B2 (en) | gM-negative EHV-mutants without heterologous elements | |
Aschner et al. | Alphaherpesvirus vaccines | |
Prichard et al. | Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs | |
US5837261A (en) | Viral vaccines | |
KRUGER et al. | Glycoproteins gI and gE of Feline Herpesvirus-1 Are Virulence Genes: Safety and Efficacy of a gI–gE− Deletion Mutant in the Natural Host | |
Zhang et al. | Protective immunity against equine herpesvirus type-1 (EHV-1) infection in mice induced by recombinant EHV-1 gD | |
US7223411B1 (en) | Herpesvirus replication defective mutants | |
Mester et al. | Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C | |
US7374768B1 (en) | Viral vaccines | |
US11390650B2 (en) | Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens | |
EP1539808B1 (de) | Gm-negative ehv-mutante ohne heterologe elementen | |
Lowry et al. | The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1 | |
Zhu | Mucosal vaccination against herpesviral infection | |
WO1996016164A1 (en) | Viral preparations, immunogens, and vaccines | |
Batra | Herpes Simplex Virus Latency: Analysis of Viral Genes Controlling Reactivation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951009 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19970929 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20000522 |